Marinus Appoints Michael R. Dougherty to its Board of Directors

February 1, 2017

Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Michael R. Dougherty to its Board of Directors.
More »

Esperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with Hypercholesterolemia

January 25, 2017

Approximately 2,000 Patients Enrolled Ahead of Schedule Following Study Expansion in October 2016 Global Study Enrolled Patients with Hypercholesterolemia with ASCVD and/or HeFH at High CVD Risk Top-Line Results Expected by Q2 2018
More »

MARINUS ANNOUNCES POSITIVE PRELIMINARY DATA FROM CHILDREN WITH CDKL5 GENETIC DISORDER

January 23, 2017

Plans to Apply for Orphan Drug Designation
More »